Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Therapeutic Strategies in Lymphoid Malignancies [[electronic resource] ] : An Immunotherapeutic Approach
| Therapeutic Strategies in Lymphoid Malignancies [[electronic resource] ] : An Immunotherapeutic Approach |
| Autore | Hillmen P |
| Pubbl/distr/stampa | Oxford, : Atlas Medical Publishing Ltd, 2005 |
| Descrizione fisica | 1 online resource (238 p.) |
| Disciplina | 616.994420637 |
| Altri autori (Persone) | WitzigTE |
| Collana | Therapeutic Strategies |
| Soggetto topico |
Cancer
Lymphatics Lymphoma Immunotherapy Lymphoproliferative Disorders Neoplasms by Histologic Type Immunomodulation Lymphatic Diseases Biological Therapy Immunoproliferative Disorders Neoplasms Immune System Diseases Diseases Therapeutics Hemic and Lymphatic Diseases Diagnostic Techniques and Procedures |
| ISBN |
1-280-30974-1
9786610309740 1-84692-556-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies
9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge 15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; Index |
| Record Nr. | UNISA-996339091503316 |
Hillmen P
|
||
| Oxford, : Atlas Medical Publishing Ltd, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Therapeutic Strategies in Lymphoid Malignancies [[electronic resource] ] : An Immunotherapeutic Approach
| Therapeutic Strategies in Lymphoid Malignancies [[electronic resource] ] : An Immunotherapeutic Approach |
| Autore | Hillmen P |
| Pubbl/distr/stampa | Oxford, : Atlas Medical Publishing Ltd, 2005 |
| Descrizione fisica | 1 online resource (238 p.) |
| Disciplina | 616.994420637 |
| Altri autori (Persone) | WitzigTE |
| Collana | Therapeutic Strategies |
| Soggetto topico |
Cancer
Lymphatics Lymphoma Immunotherapy Lymphoproliferative Disorders Neoplasms by Histologic Type Immunomodulation Lymphatic Diseases Biological Therapy Immunoproliferative Disorders Neoplasms Immune System Diseases Disease Therapeutics Hemic and Lymphatic Diseases Diagnostic Techniques and Procedures |
| ISBN |
1-280-30974-1
9786610309740 1-84692-556-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies
9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge 15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; Index |
| Record Nr. | UNINA-9910146397303321 |
|
Hillmen P
|
||
| Oxford, : Atlas Medical Publishing Ltd, 2005 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||